New concerns about medicines often prompt regulators to issue safety advisories, but a new review finds that not all advisories are created equal.
An analysis of such alerts issued by regulators in four countries — the U.S. Food and Drug Administration, Health Canada, the U.K. Medicines and Healthcare products Regulatory Agency, and the Australian Therapeutic Goods Administration — found the “overall frequency with which the regulators issued advisories differed significantly,” a team of researchers wrote in JAMA Internal Medicine.
About the Author Reprints
